Howard Feldman, MD, FRCPC, FAAN (Neurology)
Professor AdjunctAbout
Research
Overview
Medical Subject Headings (MeSH)
Dementia; Information Science; Named Groups
ORCID
0000-0002-9258-4538
Research at a Glance
Yale Co-Authors
Frequent collaborators of Howard Feldman's published research.
Publications Timeline
A big-picture view of Howard Feldman's research output by year.
James Brewer
Vladimir Coric, MD
32Publications
51Citations
Publications
2024
Varoglutamstat: Inhibiting Glutaminyl Cyclase as a Novel Target of Therapy in Early Alzheimer’s Disease
Feldman H, Messer K, Qiu Y, Sabbagh M, Galasko D, Turner R, Lopez O, Smith A, Durant J, Lupo J, Revta C, Balasubramanian A, Kuehn-Wache K, Wassmann T, Schell-Mader S, Jacobs D, Salmon D, Léger G, DeMarco M, Weber F, Group F. Varoglutamstat: Inhibiting Glutaminyl Cyclase as a Novel Target of Therapy in Early Alzheimer’s Disease. Journal Of Alzheimer's Disease 2024, 101: s79-s93. PMID: 39422941, PMCID: PMC11494639, DOI: 10.3233/jad-231126.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsGlutaminyl cyclasePost-translationallyAlzheimer's diseasePhase 2bEarly phase clinical trialsAmyloid-bCytokine monocyte chemoattractant protein-1Monocyte chemoattractant protein-1Highest tolerated doseLonger-term safetyPhase clinical trialsWeeks of treatmentFirst-in-classTarget of therapyUnique dual mechanismChemoattractant protein-1Interim futility analysisClinical efficacyDisease cascadeProtein 1Electroencephalogram changesOptimal doseClinical trialsAnalysis of cognitive functionHigh dosesA framework for translating tauopathy therapeutics: Drug discovery to clinical trials
Feldman H, Cummings J, Boxer A, Staffaroni A, Knopman D, Rizzo S, Territo P, Arnold S, Ballard C, Beher D, Boeve B, Dacks P, Diaz K, Ewen C, Fiske B, Gonzalez M, Harris G, Hoffman B, Martinez T, McDade E, Nisenbaum L, Palma J, Quintana M, Rabinovici G, Rohrer J, Rosen H, Troyer M, Kim D, Tanzi R, Zetterberg H, Ziogas N, May P, Rommel A. A framework for translating tauopathy therapeutics: Drug discovery to clinical trials. Alzheimer's & Dementia 2024 PMID: 39316411, DOI: 10.1002/alz.14250.Peer-Reviewed Original ResearchAltmetricConceptsPrimary tauopathiesClinically heterogeneous neurodegenerative diseasesTau protein aggregationHeterogeneous neurodegenerative diseaseSurrogate disease biomarkersTauopathiesProtein aggregationDefinition of rare diseasesAlzheimer's diseaseNeurodegenerative diseasesClinical trialsEarly-phase clinical trialsEarly-phase trialsDisease biomarkersFrontotemporal degenerationDrug developmentProgressive supranuclear palsyDiscovery to clinical trialsSelection of targetsTherapeuticsPharmacodynamic biomarkersRelationships between plasma biomarkers, tau PET, FDG PET, and volumetric MRI in mild to moderate Alzheimer's disease patients
Matthews D, Kinney J, Ritter A, Andrews R, Strom E, Lukic A, Koenig L, Revta C, Fillit H, Zhong K, Tousi B, Leverenz J, Feldman H, Cummings J. Relationships between plasma biomarkers, tau PET, FDG PET, and volumetric MRI in mild to moderate Alzheimer's disease patients. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2024, 10: e12490. PMID: 38988416, PMCID: PMC11233274, DOI: 10.1002/trc2.12490.Peer-Reviewed Original ResearchCitationsAltmetricConceptsFluorodeoxyglucose positron emission tomographyGlial fibrillary acidic proteinPositron emission tomographyMagnetic resonance imagingPlasma biomarkersVolumetric magnetic resonance imagingMild to moderate ADFDG positron emission tomographyPhase 2 clinical trialNeurofilament light chainGlial fibrillary acidic protein concentrationFibrillary acidic proteinInflammation-related proteinsTemporal cortexLeft inferior temporal cortexModerate ADCognitive endpointsFluorodeoxyglucosePET uptakeInflammation biomarkersBaseline MMSEMild-to-moderate Alzheimer's disease patientsImaging biomarkersBiomarker heterogeneityEmission tomographyA multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer’s Disease
Galasko D, Farlow M, Lucey B, Honig L, Elbert D, Bateman R, Momper J, Thomas R, Rissman R, Pa J, Aslanyan V, Balasubramanian A, West T, Maccecchini M, Feldman H. A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer’s Disease. Alzheimer's Research & Therapy 2024, 16: 151. PMID: 38970127, PMCID: PMC11225352, DOI: 10.1186/s13195-024-01490-z.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsOrally administered small moleculeFractional synthesis rateAscending dose studyDose-dependent loweringIRB-approved protocolEarly ADMini-Mental State ExamDose-dependent effectAlzheimer's diseaseBlood patchDouble-blindWell-toleratedCatheter placementPreclinical modelsLumbar punctureDose studyIntravenous infusionMild cognitive impairmentEvaluate safetyPlacebo participantsCognitive measuresStable isotope labeling kineticsActive drugClinical trialsADAS-Cog12Asian Cohort for Alzheimer Disease (ACAD) Pilot Study
Peavy G, Võ N, Revta C, Lu A, Lupo J, Nam P, Nguyễn K, Wang L, Feldman H. Asian Cohort for Alzheimer Disease (ACAD) Pilot Study. Alzheimer Disease & Associated Disorders 2024, 38: 277-284. PMID: 39177172, PMCID: PMC11340683, DOI: 10.1097/wad.0000000000000631.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsSubjective cognitive complaintsOlder Vietnamese AmericansVascular risk factorsMild cognitive impairmentVietnamese AmericansRisk factorsMeasuring subjective cognitive complaintsPilot studyCommunity advisory boardNongenetic risk factorsCommunity-based researchAD risk factorsAlzheimer's diseaseDepressive symptomsConsensus teamCognitive complaintsBilingual/bicultural staffAD riskAssessment toolAdvisory boardVietnamese communityExploratory analysisCognitive difficultiesCognitive impairmentParticipantsPharmacoepidemiology evaluation of bumetanide as a potential candidate for drug repurposing for Alzheimer's disease
Morales J, Gabriel N, Natarajan L, LaCroix A, Shadyab A, Xu R, Silverman J, Feldman H, Hernandez I, Aslanyan V, Bang A, Bevins E, Bowman G, Boyarko B, Chen X, Clelland C, Dodge H, Durant J, Edland S, Evans A, Galasko D, Gerwick W, Greenberg B, Herman M, Herold T, Hook V, Jacobs D, Kaye J, Kim D, Koo E, Kosik K, Léger G, Lupo J, Messer K, Momper J, Nygaard H, Pa J, Quinti L, Revta C, Rexach J, Rizzo S, Rynearson K, Schneider L, Slusher B, Tanzi R, Territo P, Yokoyama J. Pharmacoepidemiology evaluation of bumetanide as a potential candidate for drug repurposing for Alzheimer's disease. Alzheimer's & Dementia 2024, 20: 5236-5246. PMID: 39030734, PMCID: PMC11350022, DOI: 10.1002/alz.13872.Peer-Reviewed Original ResearchAltmetricConceptsRisk of ADCross-sectional analysis of electronic health recordsAnalysis of electronic health recordsAD riskAssociated with risk of ADAssociated with AD riskAssociated with decreased prevalenceElectronic health recordsRetrospective cohort study designMedicare claims dataCohort study designCox proportional hazards regressionAssociated with riskCross-sectional analysisProportional hazards regressionPrevalence of ADMultiple sensitivity analysesAlzheimer's diseaseHealth recordsMedicare beneficiariesMedicare dataClaims dataStudy designHazards regressionPatient characteristicsProtocol for a seamless phase 2A-phase 2B randomized double-blind placebo-controlled trial to evaluate the safety and efficacy of benfotiamine in patients with early Alzheimer’s disease (BenfoTeam)
Feldman H, Luchsinger J, Léger G, Taylor C, Jacobs D, Salmon D, Edland S, Messer K, Revta C, Flowers S, Jones K, Koulman A, Yarasheski K, Verghese P, Venkatesh V, Zetterberg H, Durant J, Lupo J, Gibson G, Group F. Protocol for a seamless phase 2A-phase 2B randomized double-blind placebo-controlled trial to evaluate the safety and efficacy of benfotiamine in patients with early Alzheimer’s disease (BenfoTeam). PLOS ONE 2024, 19: e0302998. PMID: 38809849, PMCID: PMC11135745, DOI: 10.1371/journal.pone.0302998.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsPhase 2bPhase 2aRandomized double-blind placebo-controlled trialDouble-blind placebo-controlled trialCo-primary efficacy endpointsTolerability eventsBest-tolerated dosePlacebo-controlled trialWell-tolerated dosesAlzheimer's diseaseLonger-term safetyEfficacy of drug deliveryWeeks of treatmentTargeted therapeutic approachesErythrocyte transketolase activityGroups of participantsDouble-blindPlacebo armEfficacy endpointSecondary endpointsOral treatmentPharmacokinetic measurementsClinical trialsTherapeutic approachesBlood markersPersonal value of Alzheimer's disease biomarker testing and result disclosure from the patient and care partner perspective
Patel K, Yang D, Feldman H, Hsiung G, Nygaard H, Best J, Dwosh E, Robillard J, DeMarco M. Personal value of Alzheimer's disease biomarker testing and result disclosure from the patient and care partner perspective. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2024, 10: e12463. PMID: 38596482, PMCID: PMC10999946, DOI: 10.1002/trc2.12463.Peer-Reviewed Original ResearchCitationsAltmetricConceptsCare partnersSemi-structured phone interviewsCare partner perspectivesCare partners' experiencesPatients' decision-making processPre-test counsellingRoutine medical careBiomarker testingHealthy behaviorsCaregiving responsibilitiesPost-disclosureRoutine carePositive lifestyleLifestyle changesPhone interviewsMedical carePartners' experiencesCarePartner's perspectiveMedical interventionsAlzheimer's diseaseObservational studyClinic patientsStudy findingsPositive feelingsClinical value of Alzheimer's disease biomarker testing
Patel K, Yang D, Best J, Chambers C, Lee P, Henri‐Bhargava A, Funnell C, Foti D, Pettersen J, Feldman H, Nygaard H, Hsiung G, DeMarco M. Clinical value of Alzheimer's disease biomarker testing. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2024, 10: e12464. PMID: 38596484, PMCID: PMC10999950, DOI: 10.1002/trc2.12464.Peer-Reviewed Original ResearchCitationsAltmetricConceptsAD biomarker testsHealth care resource useLevel of cognitive impairmentCare resource useLongitudinal cohort studyRoutine medical careAlzheimer's Disease DiagnosticHealth system economicsBiomarker testingClinical management planMedical decision-makingDementia specialistsMemory clinicIncreased referralsBaseline clinical presentationQuestionnaires pre-Increase patientsAD biomarker profileMedical careMedical utilizationFamily members' counselingManagement questionnaireCohort studyDrug prescriptionsPersonal utilityPotentially Modifiable Dementia Risk Factors in Canada: An Analysis of Canadian Longitudinal Study on Aging with a Multi-Country Comparison
Son S, Speechley M, Zou G, Kivipelto M, Mangialasche F, Feldman H, Chertkow H, Belleville S, Nygaard H, Hachinski V, Pieruccini-Faria F, Montero-Odasso M. Potentially Modifiable Dementia Risk Factors in Canada: An Analysis of Canadian Longitudinal Study on Aging with a Multi-Country Comparison. The Journal Of Prevention Of Alzheimer's Disease 2024, 11: 1490-1499. PMID: 39350396, PMCID: PMC11436427, DOI: 10.14283/jpad.2024.105.Peer-Reviewed Original ResearchAltmetricConceptsModifiable risk factorsCanadian Longitudinal StudyPhysical inactivityHearing lossDementia casesRisk factorsModifiable dementia risk factorsSleep disturbanceAssociated with modifiable risk factorsAssociated with less educationMidlife hearing lossTargeting physical inactivityDementia risk factorsDesignCross-sectional analysisLife course modelLongitudinal studyRisk reduction strategiesDementia preventionMidlife obesityMidlife hypertensionCanadian adultsLess educationPopulation impactObjectiveTo estimateTraumatic brain injury